Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Lantern Pharma Inc Market Cap
From what 1 stock analysts predict, the share price for Lantern Pharma Inc (LTRN) might increase by 415.08% in the next year. This is based on a 12-month average estimation for LTRN. Price targets go from $15 to $26. The majority of stock analysts believe LTRN is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Lantern Pharma Inc has a total of 1 Wall St Analyst ratings. There are 1 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Lantern Pharma Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of LTRN.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Emily Bodnar HC Wainwright & Co. | Neutral | Reiterates | Apr 25, 2024 | |
| Michael King EF Hutton | Buy | $11 | Reiterates | Aug 10, 2023 |
| Michael King EF Hutton | Buy | $11 | Maintains | Jun 26, 2023 |
| Michael King EF Hutton | Buy | $11 | Assumes | May 25, 2023 |
| Michael King HC Wainwright & Co. | Neutral | Initiates | May 18, 2023 | |
| Michael King EF Hutton | Buy | $11 | Reiterates | Mar 21, 2023 |
| Michael King EF Hutton | Buy | $11 | Maintains | Feb 15, 2023 |
| Michael King EF Hutton | Buy | $11 | Initiates | Nov 1, 2022 |
| Michael King HC Wainwright & Co. | Buy | $36 | Maintains | Mar 11, 2022 |
| Michael King HC Wainwright & Co. | Buy | $34 | Maintains | Nov 2, 2021 |
HC Wainwright & Co. | Buy | Initiates | Oct 7, 2021 | |
Colliers Securities | Buy | Initiates | Jul 28, 2020 |
When did it IPO
2020
Staff Count
21
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Panna Sharma PH.D.
Market Cap
$42.9M
In 2023, LTRN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that LTRN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 09 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Lantern Pharma Inc. (NASDAQ: LTRN) has enrolled its first patient in Taiwan for the Phase 2 HARMONIC™ trial, testing LP-300 in non-small cell lung cancer patients post-TKI treatment.
Why It Matters - The enrollment of the first patient in Lantern Pharma's clinical trial signals progress in cancer treatment development, potentially enhancing the company's market position and stock value.
Tue, 03 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Lantern Pharma Inc. (LTRN) received FDA Fast Track Designation for its drug candidate LP-184, aimed at treating Triple Negative Breast Cancer, marking its second designation in 2024.
Why It Matters - Fast Track Designation from the FDA accelerates LP-184's development timeline, potentially leading to quicker market entry and increased revenue for Lantern Pharma, enhancing investor confidence.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Lantern Pharma Inc. (NASDAQ: LTRN) presented new preclinical data and Phase 1b trial design for LP-184 (STAR-001) targeting glioblastoma at the SNO 2024 Annual Meeting.
Why It Matters - Lantern Pharma's advancements in LP-184 for glioblastoma could enhance its market position in oncology, potentially driving stock value and attracting investor interest in innovative cancer therapies.
Tue, 19 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Lantern Pharma (NASDAQ: LTRN) announced the first patient has been dosed in Japan for its Phase 2 HARMONIC™ trial, evaluating LP-300 in NSCLC patients who progressed after TKIs.
Why It Matters - The dosing of the first patient in Japan for Lantern Pharma's Phase 2 trial could signal progress in cancer treatment, potentially boosting the company's stock and market confidence.
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Lantern Pharma Inc. (NASDAQ: LTRN) will hold its Q3 2024 results conference call on November 7, 2024, at 4:30 PM ET, featuring key executives including the CEO and CFO.
Why It Matters - Lantern Pharma's Q3 2024 earnings call provides insights into financial performance and strategic direction, impacting stock valuation and investor sentiment in the biotech sector.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Lantern Pharma Inc. (NASDAQ: LTRN) reported operational highlights and financial results for Q3 2024, showcasing progress in its AI-driven cancer therapy programs.
Why It Matters - Lantern Pharma's operational highlights and financial results indicate strong growth and innovation in AI-driven cancer therapies, potentially increasing investor interest and stock value.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
